Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 9/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.43 |
| ▸ | APP | P05067 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.40 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2827781 | 0.93 | BACE1 (0.49) | BACE1RAB9ATSHRGPBAR1 | |
| SCHEMBL2827281 | 0.90 | TSHR (0.55) | BACE1RAB9ATSHRCYP2D6PDGFRB | |
| SCHEMBL2826364 | 0.86 | FLT3 (0.51) | RAB9AALDH1A1MAPT | |
| SCHEMBL2828891 | 0.84 | FLT3 (0.49) | RAB9ATSHRALDH1A1MAPT | |
| SCHEMBL2825483 | 0.82 | TSHR (0.56) | BACE1TSHRCYP2D6PDGFRBPDGFRA | |
| SCHEMBL2827746 | 0.80 | FLT3 (0.51) | BACE1RAB9AALDH1A1MAPT | |
| SCHEMBL2827779 | 0.79 | RAB9A (0.44) | BACE1RAB9ATSHRALDH1A1PTGS2 | |
| SCHEMBL2829272 | 0.79 | KMT2A (0.52) | RAB9ATSHRALDH1A1MAPT | |
| SCHEMBL2827069 | 0.77 | L3MBTL1 (0.48) | RAB9ATSHRALDH1A1MAPT | |
| SCHEMBL4592280 | 0.77 | KMT2A (0.53) | BACE1RAB9ATSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1948648-B1 | 3-ARYL-ISOXAZOLE-4-CARBONYL-BENZOFURANE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2010-05-05 | — | — | EP | claimed |
| EP-1948648-A2 | 3-ARYL-ISOXAZOLE-4-CARBONYL-BENZOFURAN DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-07-30 | — | — | EP | claimed |
| US-7388025-B2 | 3-aryl-isoxazole-4-carbonyl-benzofuran derivatives | HOFFMAN-LA ROCHE INC. (US) | 2008-06-17 | — | — | US | claimed |
| WO-2007054444-A2 | 3-ARYL-ISOXAZOLE-4-CARBONYL-BENZOFURAN DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-05-18 | — | — | WO | claimed |
| US-20070105922-A1 | 3-aryl-isoxazole-4-carbonyl-indole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2007-05-10 | — | — | US | claimed |
| EP-1948648-B1 | 3-ARYL-ISOXAZOLE-4-CARBONYL-BENZOFURANE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2010-05-05 | — | — | EP | disclosed |
| EP-1948648-A2 | 3-ARYL-ISOXAZOLE-4-CARBONYL-BENZOFURAN DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-07-30 | — | — | EP | disclosed |
| US-7388025-B2 | 3-aryl-isoxazole-4-carbonyl-benzofuran derivatives | HOFFMAN-LA ROCHE INC. (US) | 2008-06-17 | — | — | US | disclosed |
| WO-2007054444-A2 | 3-ARYL-ISOXAZOLE-4-CARBONYL-BENZOFURAN DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-05-18 | — | — | WO | disclosed |
| US-20070105922-A1 | 3-aryl-isoxazole-4-carbonyl-indole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105922-A1 | 3-aryl-isoxazole-4-carbonyl-indole derivatives | GABRA5, GABRA4, GABRA3 | BACE1 190/4885RAB9A 1937/4885TSHR 840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.